The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(ii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
LOTUSEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sangeetha Sundaramoorthy acquired 11,42,900 shares (approximately 5.5%) of Lotus Eye Hospital from Kavetha Sundaramoorthy at Rs 70 per share on 18 September 2025. This is an inter-se transfer within the promoter group, qualifying for exemption under Regulation 10(1)(a)(ii) of SEBI Takeover Regulations, which avoided the need for an open offer. Post-acquisition, Sangeetha's holding rose from 22.61% to 28.11%, crossing the 25% trigger threshold for Regulation 3(1). Kavetha's stake correspondingly declined from 15.11% to 9.61%. The disclosure has been filed with both BSE/NSE and SEBI within the required timelines.
This is a reshuffling of shares within the promoter family rather than a change in overall promoter control — total promoter-group holding remains largely unchanged. No open offer is triggered due to the inter-se exemption, so retail shareholders are not directly affected. The promoter group is consolidating shareholding under one family member, which may signal long-term commitment.